Drug Targeting Organ-Specific Strategies

References 369
[10] Rowland M, Tozer TN, Clinical Pharmacokinetics – Concepts and Applications. Williams and
Wilkins, Media PA, 1995.
[11] Proost JH, Wierda JMKH, Meijer DKF, J. Pharmacokinet. Biopharm. 1996, 24, 45–77.
[12] Boddy A, Aarons L, Adv. Drug Deliv. Rev. 1989, 3, 155–163.
[13] Rowland M, Benet LZ, Graham GG, J. Pharmacokinet. Biopharm. 1973, 1, 123–135.
[14] Rowland M, Leitch D, Fleming G, Smith B, J. Pharmacokinet. Biopharm. 1984, 12, 129–147.
[15] Rowland M, Drug Metab. Rev. 1984, 15, 55–74.
[16] Bischoff KB, Bull. Math. Biol. 1986, 48, 309–322.
[17] Balant LP, Gex-Fabry M, Xenobiot. 1990, 20, 1241–1257.
[18] Bourne DWA, Mathematical Modeling of Pharmacokinetic Data. Technomic Publishing, Lancaster
PA, 1995.
[19] Nestorov IA, Aarons LJ, Arundel PA, Rowland M, J. Pharmacokinet. Biopharm. 1998, 26, 21–46.
[20] Weiss M, Eur. J. Pharm. Sci. 1999, 7, 119–127.
[21] Meibohm B, Derendorf H, Int. J. Clin. Pharmacol. Ther. 1997, 35, 401–413.
[22] Goldstein A, Aronov L, Kalman SM, Principles of Drug Action: The Basis of Pharmacology. John
Wiley & Sons, New York, 1974.
[23] Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J, Clin. Pharmacol. Ther. 1979, 25, 358–371.
[24] Holford NHG, Sheiner LB, Clin. Pharmacokinet. 1981, 6, 429–453.
[25] Zhi J, Nightingale CH, Quintilliani R, J. Pharm. Sci. 1986, 75, 1063–1067.
[26] Mouton JW, Vinks AATMM, Punt NC, Antimicrob. Agents Chemother. 1997, 41, 733–738.
[27] Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M, Cancer Res. 1989, 49, 3823–3828.
[28] Nakai D, Fuse E, Suzuki H, Inaba M, Sugiyama Y, J. Drug Target. 1996, 3, 443–453.
[29] Kobayashi K, Jodrell DI, Ratain MJ, Cancer Surv. 1993, 17, 51–78.
[30] Sheiner LB, J. Pharmacokinet. Biopharm. 1984, 12, 93–118.
[31] Sheiner LB, J. Pharmacokinet. Biopharm. 1985, 13, 514–540.
[32] Sheiner LB, J. Pharmacokinet. Biopharm. 1986, 14, 539–555.
[33] Peck CC, Beal SL, Sheiner LB, Nichols AI, J. Pharmacokinet. Biopharm. 1984, 12, 545–558.
[34] Sheiner LB, Beal SL, J. Pharmacokinet. Biopharm. 1985, 13, 185–201.
[35] Jacquez JA, FASEB Fed. Proc. 1987, 46, 2477–2480.
[36] Godfrey KR, Chapman MJ, J. Pharmacokinet. Biopharm. 1989, 17, 229–267.
[37] Jacquez JA, Perry T, Am. J. Physiol. 1990, 258, E727–E736.
[38] Godfrey KR, Chapman MJ, Vajda S, J. Pharmacokinet. Biopharm. 1994, 22, 229–251.
[39] Ludden TM, Beal SL, Sheiner LB, J. Pharmacokinet. Biopharm. 1994, 22, 431–445.
[40] McMartin C, Biotherapy 1991, 3, 9–23.
[41] Magnusson S, Faerevik I, Berg T, In: Hepatic Endocytosis of Lipids and Proteins (Eds Windler
E,Greten H), pp. 189–195. W. Zuckschwerdt Verlag, München, 1992.
[42] Levy G, Pharm. Res. 1987, 4, 3–4.
[43] Zhu BT, Mol. Carcinog. 1999, 25, 1–13.
[44] Boddy AV, Aarons LJ, J. Pharmacokinet. Biopharm. 1991, 19, 355–362.
[45] Siegel RA, MacGregor RD, Hunt CA, J. Pharmacokinet. Biopharm. 1991, 19, 363–373.
[46] Rowland M, McLachlan A, J. Pharmacokinet. Biopharm. 1996, 24, 369–387.
[47] Aubrée-Lecat A, Duban MC, Demignot S, Domurado M, Fournié P, Domurado D, J. Pharmacokinet.
Biopharm. 1993, 21, 75–98.
[48] Stella VJ, Kearney AS, In: Targeted Drug Delivery (Ed. Juliano RL), pp. 71–103. Springer-Verlag,
Berlin, 1991.
[49] Breimer DD, Danhof M, Clin. Pharmacokinet. 1997, 32, 259–267.
[50] Sheiner LB, Ludden TM, Annu. Rev. Pharmacol. Toxicol. 1992, 32, 185–209.
[51] Aarons L, Balant LP, Mentré F, Morselli PL, Rowland M, Steimer J-L, Vozeh S, Eur. J. Clin. Pharmacol.
1996, 49, 251–254.
[52] Vozeh S, Steimer J-L, Rowland M, Morselli P, Mentré F, Balant LP, Aarons L, Clin. Pharmacokinet.
1996, 30, 81–93.
[53] Levy G, Clin. Pharmacokinet. 1998, 34, 323–333.
[54] Levy G, Adv. Drug Deliv. Rev. 1998, 33, 201–206.
[55] Stevens AJ, Martin SW, Brennan BS, McLachlan A, Gifford LA, Rowland M, Houston JB, Pharm.
Res. 1995, 12, 1987–1996.
[56] Nishikawa M, Yamashita F, Takakura Y, Hashida M, Sezaki H, J. Pharm. Pharmacol. 1992, 44,
396–401.
[57] Zhu H, Baxter LT, Jain RK, J. Nucl. Med. 1997, 38, 731–741.
[58] Zhu H, Jain RK, Baxter LT, J. Nucl. Med. 1998, 39, 65–76.